SCHEMBL2220946

SCHEMBL2220946

Cc1ccnc(C2(C#N)CCNCC2)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 5/20 0.38
AURKB Q96GD4 4/20 0.38
INCENP Q9NQS7 4/20 0.38
MAP3K12 Q12852 1/20 0.37
UHRF1 Q96T88 1/20 0.35
CCR1 P32246 1/20 0.35
CCR5 P51681 1/20 0.35
CCR8 P51685 1/20 0.35
OPRM1 P35372 2/20 0.34
KDM4E B2RXH2 1/20 0.33
MEN1 O00255 1/20 0.33
NOS3 P29474 1/20 0.33
NOS1 P29475 1/20 0.33
NOS2 P35228 1/20 0.33
KMT2A Q03164 1/20 0.33
WEE1 P30291 1/20 0.33
PKMYT1 Q99640 1/20 0.33
PIK3CA P42336 2/20 0.32
JAK2 O60674 1/20 0.32
LCK P06239 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13806000 0.89 UHRF1 (0.41) UHRF1CCR1CCR5CCR8OPRM1
SCHEMBL13805993 0.86 UHRF1 (0.38) MAP3K12UHRF1CCR1CCR5CCR8
SCHEMBL12173579 0.82 MAP3K12 (0.37) MAP3K12OPRM1WEE1PKMYT1PRKACA
SCHEMBL23778296 0.81 PDE4A (0.38) UHRF1CCR1CCR5CCR8OPRM1
SCHEMBL6884199 0.81 OPRM1 (0.54) CCR1CCR5CCR8OPRM1KDM4E
SCHEMBL12173585 0.78 MAP3K12 (0.40) MAP3K12WEE1PKMYT1PRKCEIDH1
SCHEMBL12173580 0.78 MAP3K12 (0.38) MAP3K12PRKCEIDH1
SCHEMBL6888915 0.77 ADRA1A (0.41) CCR1CCR5CCR8OPRM1KDM4E
SCHEMBL17727620 0.77 GPR119 (0.43) SYKKDM4ENOS3NOS1NOS2
SCHEMBL2269349 0.76 SYK (0.41) SYKAURKBINCENPUHRF1CCR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2563126-B1 HETEROCYCLIC QUINOLIZINE DERIVED M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS MERCK SHARP & DOHME (US) 2016-05-11 EP disclosed
EP-2515656-B1 AMINOBENZOQUINAZOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS MERCK SHARP & DOHME (US) 2014-08-06 EP disclosed
US-8507494-B2 Heterocyclic quinolizine derived M1 receptor positive allosteric modulators MERCK SHARP & DOHME CORP. (US) 2013-08-13 US disclosed
EP-2563126-A1 HETEROCYCLIC QUINOLIZINE DERIVED M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS Merck Sharp & Dohme Corp. (US) 2013-03-06 EP disclosed
US-8383638-B2 Aminobenzoquinazolinone M1 receptor positive allosteric modulators MERCK SHARP & DOHME (US) 2013-02-26 US disclosed
US-20130040959-A1 Heterocyclic Quinolizine Derived M1 Receptor Positive Allosteric Modulators MERCK SHARP & DOHME LLC 2013-02-14 US disclosed
WO-2012158475-A1 N-LINKED LACTAM M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS MERCK SHARP & DOHME CORP. (US) 2012-11-22 WO disclosed
EP-2515656-A1 AMINOBENZOQUINAZOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS Merck Sharp & Dohme Corp. (US) 2012-10-31 EP disclosed
US-20120264761-A1 Aminobenzoquinazolinone M1 Receptor Positive Allosteric Modulators MERCK SHARP & DOHME LLC 2012-10-18 US disclosed
US-8258135-B2 Quinolizidinone M1 receptor positive allosteric modulators MERCK SHARP & DOHME CORP. (US) 2012-09-04 US disclosed
WO-2011137049-A1 HETEROCYCLIC QUINOLIZINE DERIVED M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS MERCK SHARP & DOHME CORP. (US) 2011-11-03 WO disclosed
WO-2011084371-A1 AMINOBENZOQUINAZOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS MERCK SHARP & DOHME CORP. (US) 2011-07-14 WO disclosed
US-20100222355-A1 QUINOLIZIDINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS MERCK SHARP & DOHME LLC 2010-09-02 US disclosed
EP-2212322-A1 QUINOLIZIDINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS Merck Sharp & Dohme Corp. (US) 2010-08-04 EP disclosed
WO-2009051715-A1 QUINOLIZIDINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS MERCK & CO., INC. (US) 2009-04-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120264761-A1 Aminobenzoquinazolinone M1 Receptor Positive Allosteric Modulators CHRM1, OPRL1, MTNR1B SYK 999/4885AURKB 1196/4885INCENP 4695/4885
US-20100222355-A1 QUINOLIZIDINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS CHRM1, CHRM2, OPRL1 SYK 1234/4885AURKB 4019/4885INCENP 4253/4885
US-20130040959-A1 Heterocyclic Quinolizine Derived M1 Receptor Positive Allosteric Modulators CHRM1, OPRL1, CHRNA5 SYK 1145/4885AURKB 4342/4885INCENP 4397/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.